Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 8/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317580 | 0.82 | PTGER2 (0.38) | PTGER2PTGER3OPRM1OPRD1OPRK1 | |
| SCHEMBL3402623 | 0.82 | PTGER2 (0.45) | PTGER2PTGER3OPRM1OPRD1OPRK1 | |
| SCHEMBL13232170 | 0.75 | PTGER2 (0.46) | PTGER2PTGER3 | |
| SCHEMBL10021104 | 0.75 | PTGER2 (0.46) | PTGER2PTGER3OPRM1OPRD1OPRK1 | |
| SCHEMBL10021107 | 0.74 | PTGER2 (0.41) | PTGER2PTGER3 | |
| SCHEMBL13232169 | 0.74 | PTGER2 (0.41) | PTGER2PTGER3 | |
| SCHEMBL1396559 | 0.73 | PTGER2 (0.37) | PTGER2PTGER3 | |
| SCHEMBL14368236 | 0.73 | OPRL1 (0.48) | PTGER2PTGER3OPRM1OPRD1OPRK1 | |
| SCHEMBL13313985 | 0.73 | PTGER2 (0.40) | PTGER2PTGER3 | |
| SCHEMBL1145769 | 0.72 | CETP (0.34) | PTGER2PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | claimed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | claimed |
| EP-2118094-B1 | GAMMA-LACTAMS FOR THE TREATMENT OF GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | claimed |
| EP-2257548-B1 | THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-7956051-B2 | Therapeutic amides and related compounds | ALLERGAN, INC. (US) | 2011-06-07 | — | — | US | claimed |
| EP-2247583-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2010-11-10 | — | — | EP | claimed |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-06-03 | — | — | US | claimed |
| EP-2121609-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | Allergan, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2009094286-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2009-07-30 | — | — | WO | claimed |
| US-20090192151-A1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. | 2009-07-30 | — | — | US | claimed |
| WO-2008091818-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-31 | — | — | WO | claimed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2027081-B1 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2285775-B1 | Lactams and their use in the treatment of inter alia ocular hypertension or baldness | ALLERGAN INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20070259929-A1 | Therapeutic Compounds | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| WO-2007115020-A2 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | PTGIS, PTGIR, CYP11B2 | PTGER2 48/4885PTGER3 124/4885OPRM1 1119/4885 |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | PTGER2 1343/4885PTGER3 2592/4885OPRM1 1473/4885 |
| US-20070259929-A1 | Therapeutic Compounds | PIGO, CYC1, COXFA4L2 | PTGER2 456/4885PTGER3 442/4885OPRM1 778/4885 |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | PTGER2 1449/4885PTGER3 1850/4885OPRM1 713/4885 |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | PTGER2 1343/4885PTGER3 2592/4885OPRM1 1473/4885 |
| US-20090192151-A1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | VIP, SHH, GLI1 | PTGER2 475/4885PTGER3 828/4885OPRM1 2483/4885 |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | PTGER2 995/4885PTGER3 2164/4885OPRM1 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.